Try our mobile app

NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS

Published: 2022-08-29 07:10:00 ET
<<<  go to AMGN company page

Earlier Treatment With Repatha Resulted in a Lower Incidence of Major CV Events, Including CV Death

80% of Patients Achieved Guideline Directed LDL-C Levels of